Important Implication in Cancer Immunotherapy

Slides:

Advertisements

Similar presentations

Antigen Presentation K.J. Goodrum Department of Biomedical Sciences Ohio University 2005.

Advertisements

Introduction to Immunology

Bioinformatics pipeline for detection of immunogenic cancer mutations by high throughput mRNA sequencing Jorge Duitama 1, Ion Mandoiu 1, and Pramod Srivastava.

T Cell Receptor (TCR) & MHC Complexes-Antigen Presentation

Antigen recognition by T cells Zheng W. Chen, M.D., Ph.D.

Dr. Adel Al-Mogren 1.

Manufacture of Human Interleukin 13 Protein Using a Prokaryotic Expression System Ryan Rupp, York College of Pennsylvania, Department of Biological Sciences.

بسم الله الرحمن الرحيم. Cancer Origin and Terminology Malignant Transformation of Cells Oncogenes and Cancer Induction Tumor Antigens Immune Responses.

Identification of Cancer-Specific Motifs in

Dr. Adel Al-Mogren 1.

CD8+ T Cells Contribute to Lung Cancer Progression in a PD-1 Dependent Fashion Stephanie Chang, Saeed Arefanian, Ryuji Higashikubo, Daniel Kreisel, Andrew.

Computational methods for genomics-guided immunotherapy Sahar Al Seesi Computer Science & Engineering Department, UCONN Immunology Department, UCONN Health.

T Cell Receptor (TCR) & MHC Complexes-Antigen Presentation Pin Ling ( 凌斌 ), Ph.D. ext 5632; References: 1. Abbas, A, K. et.al,

Eric S. Huseby et al, Cell (2005); Nature Immunol. (2007), compared the T cells of normal mice, with mice genetically engineered to present only one type.

PHASE I VACCINATION TRIAL OF SYT-SSX JUNCTION PEPTIDE AND ITS HLA-A*2402 ANCHOR SUBSTITUTE IN PATIENTS WITH DISSEMINATED SYNOVIAL SARCOMA Kawaguchi S,

The Retinoblastoma Protein

Mechanisms of T Cell Tolerance

Cancer Vaccine Design Ion Mandoiu

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

T cell receptor & MHC complexes-Antigen presentation

Chapter 7. 주조직적합성 복합체 1. 주조직적합성 복합체 (MHC)의 발견 2. MHC 분자의 구조

T Cell Receptor (TCR) & MHC Complexes-Antigen Presentation

Socializing Individualized T-Cell Cancer Immunotherapy

Intracellular Pathogens Extracellular Pathogens

COMPLICATIONS OF IMMUNOTHERAPY IN THE HOSPITALIZED PATIENT Vivek Batra MD, Emma Weaver MD Division of Medical Oncology, Thomas Jefferson University, Philadelphia.

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Overview of next-generation sequencing, neoantigen prediction, and functional T-cell analyses. Overview of next-generation sequencing, neoantigen prediction,

TCR-MHC-peptide(s): in vivo veritas

Supplementary figure 1. Gating strategy used for FACS sorting of TIL subsets (CD3+, CD3+CD8+/-, CD3+CD8+PD-1+/-). Two representative fresh tumor samples.

Man's Best Friend: Utilizing Naturally Occurring Tumors in Dogs to Improve Chimeric Antigen Receptor T-cell Therapy for Human Cancers Melinda Mata, Stephen.

Landscape overview of GENIE dataset.

Expansion and isolation of NY-ESO-1–specific T cell clones.

The Dog as a Model of Human Cancer

Engineering regulatory T cells against factor VIII inhibitors

Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma Darshil J. Shah, MD, MPH, Roxana S. Dronca,

Experimental methods in classic epitope discovery

Megan E. Daly, MD, Arta M. Monjazeb, MD, PhD, Karen Kelly, MD

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

Biomarkers in Cancer Immunotherapy

Applications of Immunogenomics to Cancer

Potential clinical actionability.

Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.

Takehito Shukuya, MD, PhD, David P. Carbone, MD, PhD

Volume 26, Issue 2, Pages (February 2018)

Neoantigen-specific TCR expansion in stimulated T-cell cultures.

Mechanism of CTLA-4-induced immunosuppression.

Whole-exome sequencing identifies NF1 mutations in tumors of melanoma patients exhibiting resistance to vemurafenib. Whole-exome sequencing identifies.

Nat. Rev. Endocrinol. doi: /nrendo

Cancer is a Challenge Cancer is common in humans – a public health problem ~1 of every 3 women will develop cancer ~1 of every 2 men will develop cancer.

T-cell receptor contact and MHC binding residues of a major rye grass pollen allergen T- cell epitope Matthew D. Burton, BSC, Hons, Bella Blaher, PhD,,

Comparison of mapped epitopes and peptides identified in immuno-SILAC screening of polyclonal antibodies against trypsin-digested PrESTs. Comparison of.

Fig. 1 Cancer exome–based identification of neoantigens.

Teaching an Old Drug New Tricks:

Utilizing NGS-Data to Evaluate Anti-PD-1 Treatment

Claude Daniel, Stephen Horvath, Paul M Allen Immunity

Antigen presentation of the immunodominant T-cell epitope of the major mugwort pollen allergen, Art v 1, is associated with the expression of HLA-DRB1∗01

Cancer Evolution during Immunotherapy

Closing Remarks Paul Lunn Dean, College of Veterinary Medicine

Imaging cycling hypoxia in canine tumors during radiotherapy dosing

Distribution of immune checkpoint in tumor cells and immune microenvironment. CTLA-4, cytotoxic T lymphocyte antigen-4; MHC, major histocompatibility complex;

Releasing the Brakes on Cancer Immunotherapy

Immune pathomechanism of drug hypersensitivity reactions

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Brenda S. Kennedy DVM MS Director of Canine Health and Research

Oncogenic BRAF mutations have been described in approximately 8% of human cancers, including at least 50% of melanoma. Oncogenic BRAF mutations have been.

T-cell-receptor cross-recognition and strategies to select safe T-cell receptors for clinical translation Amalie Kai Bentzen, Sine Reker Hadrup Immuno-Oncology.

Fig. 1 Cancer exome–based identification of neoantigens.

Investigation of reactivity of D14 HLA-A

Low initial levels of CD4+ Tregs, proliferating CD8+, and Granzyme B+ CD8+ T cells and high posttreatment tumor MHC class II expression predict better.

Presentation transcript:

Important Implication in Cancer Immunotherapy The prevalent Boxer MHC class I Dog Leukocyte Antigen (DLA)-88*034:01 preferentially binds nonamer peptides with a defined motif Important Implication in Cancer Immunotherapy Paige Nemec NCSU Ph.D. Student Department of Clinical Sciences Consortium for Canine Comparative Oncology (C3O) Symposium Durham Convention Center February 23, 2018

Tumor cells Cytotoxic T Cells T Cell Lymphoma Glioma

FLAG PN62 clone expressing FLAG-tagged DLA-88*034:01 Sequenced peptides by tandem mass spectrometry 9-mers preferred Alkaline eluted & purified peptides

Motif Discovery Anchor Anchor TCR Interaction

Tumor Antigen: B-RAF For reference, the V595 position that mutates to E in urothelial carcinomas is shown in blue. ….SIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKRDERPLFPPQILASIELLARSLPKIHRSASEP… non-synonymous substitution K695I in Boxer melanoma …LATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPV… …LATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKIRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPV…

Acknowledgments Dr. Paul Hess Jennifer Holmes Alex Kapatos Duke University Proteomics and Metabolomics Core Facility Greg Waitt Arthur Mosley Eric Soderblom American Kennel Club Canine Health Foundation